Our Research

Image of decoding adult brain tumor invasion and drug response

Reconstructing the Single-Cell Spatiotemporal Dynamics of Glioblastoma Invasion

By integrating whole-specimen confocal microscopy, vascular counterstaining, and an advanced computational pipeline combining convolutional neural networks and Hidden Markov Models, our newly developed method GlioTrace identifies distinct invasion modes, including dynamic morphological switching, vessel-guided migration, and immune cell interactions and quantifies patient-specific variations in invasion plasticity. Using our method, we demonstrate that targeted therapies can selectively modulate invasion phenotypes, revealing spatially and temporally distinct drug responses. This scalable platform provides an unprecedented window into glioblastoma progression and treatment response, offering a powerful tool for precision oncology and anti-invasion therapeutic development.

Image of data-driven drug discovery for pediatric neural cancers — **Data-driven drug discovery for pediatric neural cancers**

Our team is exploring how innovative analyses of big data sets can be used to discover new therapeutics. In one of our recent projects, we developed a new algorithm, TargetTranslator, which could identify new treatments for neuroblastoma (Almstedt et al, Nature Communications 2020). Our current work explores how data-driven methods can be used to target a broader range of pediatric cancer, including medulloblastoma and DIPG. Our team has invented several other tools for data-driven cancer research, such as CancerLandscapes, EPoC, and CoPIA.

Decoding adult brain tumor invasion and drug response.

Our team is pioneering the use of patient-derived cell biobanks as a tool to uncover growth and drug response in the brain tumor glioblastoma (Cell Reports 2020, NeuroOncology 2018, Science Translational Medicine 2015, EBioMedicine 2015,). In recent work, we used our in-house Uppsala-based biobank HGCC to report on pharmacological subtypes of GBM. We are currently using the HGCC models to uncover differences in brain tumor invasion, using several different approaches. A key goal is to uncover the genetic programs that mediate invasion along different anatomical routes, including single-cell /spatial methods, CRISPR, and computational modeling. The key directions are:

Uncovering regulators of route-specific brain tumor invasion.
The emergence of macroscopic brain tumor phenotypes from microscopic cell behavior.
Route-specific routes of drug delivery.

Image of brain tumor systems biology research

Our team is investigating how tumor heterogeneity and drug response depends on time-dependent changes in individual tumor cells. In a recent study (Molecular Systems Biology, 2021), we have proposed a new strategy to construct models of cellular hierarchies from barcoded single cell experiments. The models, which we call State Transition and Growth models, are fitted from experimental data, obtained using barcoded single-cell sequencing and optical reporters. STAG models may have several potential uses in tumor biology and drug development.

Our Team

Sven Nelander, PI

Sven Nelander is a cross-disciplinary scientist focused on understanding, modeling, and treating brain cancers. With a background in medicine and mathematics, his research applies mathematical and experimental techniques to identify mechanisms and therapeutic targets, emphasizing cellular reprogramming to suppress tumor growth and improve therapies. Originally from southern Sweden, Sven studied medicine and mathematics in Lund before earning a Ph.D. in developmental processes in Gothenburg, doing early work in decoding cell type-specific gene regulation. As a postdoc in Chris Sander’s lab and later as an independent investigator, he invented new ways of modeling how cancer cells integrate perturbations from mutation, treatment, and stress. Since joining Uppsala University and SciLifeLab in 2012, Sven has built a research program linking tumor biobanking and neuro-oncology with modern systems biology, with support from several major foundations. He also serves as the founding director of CNSx3, a national center advancing modeling approaches for brain diseases. Outside the lab, Sven enjoys time with family, running, mushroom foraging, and restoring his summer house. He’s also an avid watercolorist with a passion for capturing light and fleeting moments in pigments.

Irem Uppman

Irem Uppman is a PhD student in Nelander lab. A molecular biologist by background, Irem is interested in investigating cell-states and clonal evolution in primary brain tumors. Her main projects focus on cell-state plasticity and invasion in adult and pediatric high-grade gliomas. She hopes to continue her career in research and contribute to our understanding of brain malignancies. In her free time, Irem likes to read (very quickly), knit (very slowly), take care of her plants (very poorly) and spend time with friends and family.

Anders Sundström

Anders Sundström is a bioinformatician working predominantly across the omics landscape along some ventures into system biology and image analysis. Since 2015, he has been part of the Neuro-Oncology program at the Department of Immunology, Genetics, and Pathology at Uppsala University. In his parallel personal journey, he spent a year at art school where he participated in a group exhibition at the Iziko National Gallery of South Africa, earned a green belt in capoeira and became a two-time champion in the international Gagarin Cup floorball tournament.

Madeleine Skeppås

Madeleine started as a computational PhD student in Nelander lab in 2023, after earning her M.Sc. in Biophysics from Uppsala University the same year. Her work is focused on leveraging machine learning and image analysis to investigate the morphological and transcriptional heterogeneity and plasticity in glioblastoma. Her most recent work involves developing a method of single-cell tracking for in vitro and ex vivo settings, with the goal of following fluctuations in cellular morphology and protein expression over time. Outside of work, Madeleine dedicates most of her time to catching up with family and friends, as well as taking the occasional forest bath.

Hitesh Mangukiya

Hitesh Mangukiya specializes in studying the complex interactions between tumor cells, vascular cells, and microglia, with a focus on cell dynamics and invasion in glioblastoma. His current research centers on investigating cell dynamics, characterizing patient-specific tumor-endothelial interactions, and enhancing our understanding of glioblastoma’s invasive nature.

Josephine Heinold

Josephine Heinold is a new Ph.D student in Sven Nelander’s group focusing on plastic changes of cell states in GBM and DMG based on CRISPR-Tag genome editing. Originally from Germany, she completed her bachelor in pharmaceutical Biotechnology in a small town called Biberach an der Riss. She continued her education at Uppsala University in molecular medicine focusing on cancer mechanisms at a molecular level. Josi likes to try to do it all in her free time by jumping from knitting, to half-marathons ending up playing the accordion to let her creativity flow while also keeping her house plants alive. She also loves to ‘keep the tan up’ by traveling to warmer places in the summer.

Rebecka Stockgard

Rebecka is a PhD student in Nelander lab.

Selected Publications

Almstedt E, Rosén E, Gloger M, Stockgard R, Hekmati N, Koltowska K, Krona C, Nelander S. Real-time evaluation of glioblastoma growth in patient-specific zebrafish xenografts. Neuro Oncol. 2022 May 4;24(5):726-738.
Vinel C, Rosser G, Guglielmi L, Constantinou M, Pomella N, Zhang X, Boot JR, Jones TA, Millner TO, Dumas AA, Rakyan V, Rees J, Thompson JL, Vuononvirta J, Nadkarni S, El Assan T, Aley N, Lin YY, Liu P, Nelander S, Sheer D, Merry CLR, Marelli-Berg F, Brandner S, Marino S. Comparative epigenetic analysis of tumour initiating cells and syngeneic EPSC-derived neural stem cells in glioblastoma. Nat Commun. 2021 Oct 21;12(1):6130.
Gerlee P, Altrock PM, Malik A, Krona C, Nelander S. Autocrine signaling can explain the emergence of Allee effects in cancer cell populations. PLoS Comput Biol. 2022 Mar 3;18(3):e1009844.
Larsson I, Dalmo E, Elgendy R, Niklasson M, Doroszko M, Segerman A, Jörnsten R, Westermark B, Nelander S. Modeling glioblastoma heterogeneity as a dynamic network of cell states. Mol Syst Biol. 2021 Sep;17(9):e10105.
Marques C, Unterkircher T, Kroon P, Oldrini B, Izzo A, Dramaretska Y, Ferrarese R, Kling E, Schnell O, Nelander S, Wagner EF, Bakiri L, Gargiulo G, Carro MS, Squatrito M. NF1 regulates mesenchymal glioblastoma plasticity and aggressiveness through the AP-1 transcription factor FOSL1. Elife. 2021 Aug 17;10:e64846.
Seçilmiş D, Hillerton T, Nelander S, Sonnhammer ELL. Inferring the experimental design for accurate gene regulatory network inference. Bioinformatics. 2021 May 12:btab367.
Merisaari J, Denisova OV, Doroszko M, Le Joncour V, Johansson P, Leenders WPJ, Kastrinsky DB, Zaware N, Narla G, Laakkonen P, Nelander S, Ohlmeyer M, Westermarck J. Monotherapy efficacy of blood-brain barrier permeable small molecule reactivators of protein phosphatase 2A in glioblastoma. Brain Commun. 2020 Jan 11;2(1):fcaa002.
Johansson P, Krona C, Kundu S, Doroszko M, Baskaran S, Schmidt L, Vinel C, Almstedt E, Elgendy R, Elfineh L, Gallant C, Lundsten S, Ferrer Gago FJ, Hakkarainen A, Sipilä P, Häggblad M, Martens U, Lundgren B, Frigault MM, Lane DP, Swartling FJ, Uhrbom L, Nestor M, Marino S, Nelander S. A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma. Cell Rep. 2020 Jul 14;32(2):107897.
Johard H, Omelyanenko A, Fei G, Zilberter M, Dave Z, Abu-Youssef R, Schmidt L, Harisankar A, Vincent CT, Walfridsson J, Nelander S, Harkany T, Blomgren K, Andäng M. HCN Channel Activity Balances Quiescence and Proliferation in Neural Stem Cells and Is a Selective Target for Neuroprotection During Cancer Treatment. Mol Cancer Res. 2020 Oct;18(10):1522-1533.
Dalmo E, Johansson P, Niklasson M, Gustavsson I, Nelander S, Westermark B. Growth-Inhibitory Activity of Bone Morphogenetic Protein 4 in Human Glioblastoma Cell Lines Is Heterogeneous and Dependent on Reduced SOX2 Expression. Mol Cancer Res. 2020 Jul;18(7):981-991. doi: 10.1158/1541-7786.MCR-19-0638.
Almstedt E, Elgendy R, Hekmati N, Rosén E, Wärn C, Olsen TK, Dyberg C, Doroszko M, Larsson I, Sundström A, Arsenian Henriksson M, Påhlman S, Bexell D, Vanlandewijck M, Kogner P, Jörnsten R, Krona C, Nelander S. Integrative discovery of treatments for high-risk neuroblastoma. Nat Commun. 2020 Jan 3;11(1):71. doi: 10.1038/s41467-019-13817-8. PMID: 31900415; PMCID: PMC6941971.
Čančer M, Drews LF, Bengtsson J, Bolin S, Rosén G, Westermark B, Nelander S, Forsberg-Nilsson K, Uhrbom L, Weishaupt H, Swartling FJ. BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells. Cell Death Dis. 2019 Nov 21;10(12):881. doi: 10.1038/s41419-019-2120-1. PMID: 31754113; PMCID: PMC6872649.
Kaffes I, Szulzewsky F, Chen Z, Herting CJ, Gabanic B, Velázquez Vega JE, Shelton J, Switchenko JM, Ross JL, McSwain LF, Huse JT, Westermark B, Nelander S, Forsberg-Nilsson K, Uhrbom L, Maturi NP, Cimino PJ, Holland EC, Kettenmann H, Brennan CW, Brat DJ, Hambardzumyan D. Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors. Oncoimmunology. 2019 Aug 22;8(11):e1655360. doi: 10.1080/2162402X.2019.1655360. PMID: 31646100; PMCID: PMC6791439.
Mega A, Hartmark Nilsen M, Leiss LW, Tobin NP, Miletic H, Sleire L, Strell C, Nelander S, Krona C, Hägerstrand D, Enger PØ, Nistér M, Östman A. Astrocytes enhance glioblastoma growth. Glia. 2020 Feb;68(2):316-327. doi: 10.1002/glia.23718. Epub 2019 Sep 11. PMID: 31509308.
Munksgaard Thorén M, Chmielarska Masoumi K, Krona C, Huang X, Kundu S, Schmidt L, Forsberg-Nilsson K, Floyd Keep M, Englund E, Nelander S, Holmqvist B, Lundgren-Åkerlund E. Integrin α10, a Novel Therapeutic Target in Glioblastoma, Regulates Cell Migration, Proliferation, and Survival. Cancers (Basel). 2019 Apr 25;11(4):587. doi: 10.3390/cancers11040587. PMID: 31027305; PMCID: PMC6521287.
Nelander S. Increasing the accuracy of glioblastoma subtypes: Factoring in the tumor's cell of origin. Mol Cell Oncol. 2018 Nov 27;6(1):1302907. doi: 10.1080/23723556.2017.1302907. PMID: 30788413; PMCID: PMC6370376.
Weishaupt H, Johansson P, Sundström A, Lubovac-Pilav Z, Olsson B, Nelander S, Swartling FJ. Batch-normalization of cerebellar and medulloblastoma gene expression datasets utilizing empirically defined negative control genes. Bioinformatics. 2019 Sep 15;35(18):3357-3364. doi: 10.1093/bioinformatics/btz066. PMID: 30715209; PMCID: PMC6748729.
Xie Y, Sundström A, Maturi NP, Tan EJ, Marinescu VD, Jarvius M, Tirfing M, Jin C, Chen L, Essand M, Swartling FJ, Nelander S, Jiang Y, Uhrbom L. LGR5 promotes tumorigenicity and invasion of glioblastoma stem-like cells and is a potential therapeutic target for a subset of glioblastoma patients. J Pathol. 2019 Feb;247(2):228-240. doi: 10.1002/path.5186. Epub 2019 Jan 10. PMID: 30357839.
Matuszewski DJ, Wählby C, Krona C, Nelander S, Sintorn IM. Image-Based Detection of Patient-Specific Drug-Induced Cell-Cycle Effects in Glioblastoma. SLAS Discov. 2018 Dec;23(10):1030-1039. doi: 10.1177/2472555218791414. Epub 2018 Aug 3. PMID: 30074852.
Baskaran S, Mayrhofer M, Kultima HG, Bergström T, Elfineh L, Cavelier L, Isaksson A, Nelander S. Primary glioblastoma cells for precision medicine: a quantitative portrait of genomic (in)stability during the first 30 passages. Neuro Oncol. 2018 Jul 5;20(8):1080-1091. doi: 10.1093/neuonc/noy024. PMID: 29462414; PMCID: PMC6280139.
Lönnstedt IM, Nelander S. FC1000: normalized gene expression changes of systematically perturbed human cells. Stat Appl Genet Mol Biol. 2017 Sep 26;16(4):217-242. doi: 10.1515/sagmb-2016-0072. PMID: 28862994.
Fedele V, Dai F, Masilamani AP, Heiland DH, Kling E, Gätjens-Sanchez AM, Ferrarese R, Platania L, Soroush D, Kim H, Nelander S, Weyerbrock A, Prinz M, Califano A, Iavarone A, Bredel M, Carro MS. Epigenetic Regulation of ZBTB18 Promotes Glioblastoma Progression. Mol Cancer Res. 2017 Aug;15(8):998-1011. doi: 10.1158/1541-7786.MCR-16-0494. Epub 2017 May 16. PMID: 28512252; PMCID: PMC5967621.
Jiang Y, Marinescu VD, Xie Y, Jarvius M, Maturi NP, Haglund C, Olofsson S, Lindberg N, Olofsson T, Leijonmarck C, Hesselager G, Alafuzoff I, Fryknäs M, Larsson R, Nelander S, Uhrbom L. Glioblastoma Cell Malignancy and Drug Sensitivity Are Affected by the Cell of Origin. Cell Rep. 2017 Jan 24;18(4):977-990. doi: 10.1016/j.celrep.2017.01.003. Erratum in: Cell Rep. 2017 May 2;19(5):1080-1081. PMID: 28122246.
Niklasson M, Maddalo G, Sramkova Z, Mutlu E, Wee S, Sekyrova P, Schmidt L, Fritz N, Dehnisch I, Kyriatzis G, Krafcikova M, Carson BB, Feenstra JM, Marinescu VD, Segerman A, Haraldsson M, Gustavsson AL, Hammarström LG, Jenmalm Jensen A, Uhrbom L, Altelaar AF, Linnarsson S, Uhlén P, Trantirek L, Vincent CT, Nelander S, Enger PØ, Andäng M. Membrane-Depolarizing Channel Blockers Induce Selective Glioma Cell Death by Impairing Nutrient Transport and Unfolded Protein/Amino Acid Responses. Cancer Res. 2017 Apr 1;77(7):1741-1752. doi: 10.1158/0008-5472.CAN-16-2274. Epub 2017 Jan 13. PMID: 28087597.
Kling T, Ferrarese R, Ó hAilín D, Johansson P, Heiland DH, Dai F, Vasilikos I, Weyerbrock A, Jörnsten R, Carro MS, Nelander S. Integrative Modeling Reveals Annexin A2-mediated Epigenetic Control of Mesenchymal Glioblastoma. EBioMedicine. 2016 Oct;12:72-85. doi: 10.1016/j.ebiom.2016.08.050. Epub 2016 Sep 18. PMID: 27667176; PMCID: PMC5078587.
Schmidt L, Baskaran S, Johansson P, Padhan N, Matuszewski D, Green LC, Elfineh L, Wee S, Häggblad M, Martens U, Westermark B, Forsberg-Nilsson K, Uhrbom L, Claesson-Welsh L, Andäng M, Sintorn IM, Lundgren B, Lönnstedt I, Krona C, Nelander S. Case-specific potentiation of glioblastoma drugs by pterostilbene. Oncotarget. 2016 Nov 8;7(45):73200-73215. doi: 10.18632/oncotarget.12298. PMID: 27689322; PMCID: PMC5341973.
Ramachandran M, Yu D, Dyczynski M, Baskaran S, Zhang L, Lulla A, Lulla V, Saul S, Nelander S, Dimberg A, Merits A, Leja-Jarblad J, Essand M. Safe and Effective Treatment of Experimental Neuroblastoma and Glioblastoma Using Systemically Delivered Triple MicroRNA-Detargeted Oncolytic Semliki Forest Virus. Clin Cancer Res. 2017 Mar 15;23(6):1519-1530. doi: 10.1158/1078-0432.CCR-16-0925. Epub 2016 Sep 16. PMID: 27637889.
Allen M, Bjerke M, Edlund H, Nelander S, Westermark B. Origin of the U87MG glioma cell line: Good news and bad news. Sci Transl Med. 2016 Aug 31;8(354):354re3. doi: 10.1126/scitranslmed.aaf6853. PMID: 27582061.
Padhan N, Nordling TE, Sundström M, Åkerud P, Birgisson H, Nygren P, Nelander S, Claesson-Welsh L. High sensitivity isoelectric focusing to establish a signaling biomarker for the diagnosis of human colorectal cancer. BMC Cancer. 2016 Aug 25;16(1):683. doi: 10.1186/s12885-016-2725-z. PMID: 27562229; PMCID: PMC5000422.
Wee B, Pietras A, Ozawa T, Bazzoli E, Podlaha O, Antczak C, Westermark B, Nelander S, Uhrbom L, Forsberg-Nilsson K, Djaballah H, Michor F, Holland EC. ABCG2 regulates self-renewal and stem cell marker expression but not tumorigenicity or radiation resistance of glioma cells. Sci Rep. 2016 Jul 26;6:25956. doi: 10.1038/srep25956. PMID: 27456282; PMCID: PMC4960591.
Mitchell JS, Li N, Weinhold N, Försti A, Ali M, van Duin M, Thorleifsson G, Johnson DC, Chen B, Halvarsson BM, Gudbjartsson DF, Kuiper R, Stephens OW, Bertsch U, Broderick P, Campo C, Einsele H, Gregory WA, Gullberg U, Henrion M, Hillengass J, Hoffmann P, Jackson GH, Johnsson E, Jöud M, Kristinsson SY, Lenhoff S, Lenive O, Mellqvist UH, Migliorini G, Nahi H, Nelander S, Nickel J, Nöthen MM, Rafnar T, Ross FM, da Silva Filho MI, Swaminathan B, Thomsen H, Turesson I, Vangsted A, Vogel U, Waage A, Walker BA, Wihlborg AK, Broyl A, Davies FE, Thorsteinsdottir U, Langer C, Hansson M, Kaiser M, Sonneveld P, Stefansson K, Morgan GJ, Goldschmidt H, Hemminki K, Nilsson B, Houlston RS. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nat Commun. 2016 Jul 1;7:12050. doi: 10.1038/ncomms12050. PMID: 27363682; PMCID: PMC4932178.
Gerlee P, Nelander S. Travelling wave analysis of a mathematical model of glioblastoma growth. Math Biosci. 2016 Jun;276:75-81. doi: 10.1016/j.mbs.2016.03.004. Epub 2016 Mar 25. PMID: 27021919.
Darmanis S, Gallant CJ, Marinescu VD, Niklasson M, Segerman A, Flamourakis G, Fredriksson S, Assarsson E, Lundberg M, Nelander S, Westermark B, Landegren U. Simultaneous Multiplexed Measurement of RNA and Proteins in Single Cells. Cell Rep. 2016 Jan 12;14(2):380-9. doi: 10.1016/j.celrep.2015.12.021. Epub 2015 Dec 31. PMID: 26748716; PMCID: PMC4713867.
Xie Y, Bergström T, Jiang Y, Johansson P, Marinescu VD, Lindberg N, Segerman A, Wicher G, Niklasson M, Baskaran S, Sreedharan S, Everlien I, Kastemar M, Hermansson A, Elfineh L, Libard S, Holland EC, Hesselager G, Alafuzoff I, Westermark B, Nelander S, Forsberg-Nilsson K, Uhrbom L. The Human Glioblastoma Cell Culture Resource: Validated Cell Models Representing All Molecular Subtypes. EBioMedicine. 2015 Aug 15;2(10):1351-63. doi: 10.1016/j.ebiom.2015.08.026. PMID: 26629530; PMCID: PMC4634360.
Swaminathan B, Thorleifsson G, Jöud M, Ali M, Johnsson E, Ajore R, Sulem P, Halvarsson BM, Eyjolfsson G, Haraldsdottir V, Hultman C, Ingelsson E, Kristinsson SY, Kähler AK, Lenhoff S, Masson G, Mellqvist UH, Månsson R, Nelander S, Olafsson I, Sigurðardottir O, Steingrimsdóttir H, Vangsted A, Vogel U, Waage A, Nahi H, Gudbjartsson DF, Rafnar T, Turesson I, Gullberg U, Stefánsson K, Hansson M, Thorsteinsdóttir U, Nilsson B. Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma. Nat Commun. 2015 May 26;6:7213. doi: 10.1038/ncomms8213. PMID: 26007630; PMCID: PMC4455110.
Kling T, Johansson P, Sanchez J, Marinescu VD, Jörnsten R, Nelander S. Efficient exploration of pan-cancer networks by generalized covariance selection and interactive web content. Nucleic Acids Res. 2015 Sep 3;43(15):e98. doi: 10.1093/nar/gkv413. Epub 2015 May 7. PMID: 25953855; PMCID: PMC4551906.
Studham ME, Tjärnberg A, Nordling TE, Nelander S, Sonnhammer EL. Functional association networks as priors for gene regulatory network inference. Bioinformatics. 2014 Jun 15;30(12):i130-8. doi: 10.1093/bioinformatics/btu285. PMID: 24931976; PMCID: PMC4058914.
Cvijovic M, Almquist J, Hagmar J, Hohmann S, Kaltenbach HM, Klipp E, Krantz M, Mendes P, Nelander S, Nielsen J, Pagnani A, Przulj N, Raue A, Stelling J, Stoma S, Tobin F, Wodke JA, Zecchina R, Jirstrand M. Bridging the gaps in systems biology. Mol Genet Genomics. 2014 Oct;289(5):727-34. doi: 10.1007/s00438-014-0843-3. Epub 2014 Apr 13. PMID: 24728588.
Schmidt L, Kling T, Monsefi N, Olsson M, Hansson C, Baskaran S, Lundgren B, Martens U, Häggblad M, Westermark B, Forsberg Nilsson K, Uhrbom L, Karlsson- Lindahl L, Gerlee P, Nelander S. Comparative drug pair screening across multiple glioblastoma cell lines reveals novel drug-drug interactions. Neuro Oncol. 2013 Nov;15(11):1469-78. doi: 10.1093/neuonc/not111. Epub 2013 Oct 6. PMID: 24101737; PMCID: PMC3813417.
Cancer Genome Atlas Research Network, The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013 Oct;45(10):1113-20. doi: 10.1038/ng.2764. PMID: 24071849; PMCID: PMC3919969.
Gerlee P, Schmidt L, Monsefi N, Kling T, Jörnsten R, Nelander S. Searching for synergies: matrix algebraic approaches for efficient pair screening. PLoS One. 2013 Jul 25;8(7):e68598. doi: 10.1371/journal.pone.0068598. PMID: 23935877; PMCID: PMC3723843.
Gerlee P, Nelander S. The impact of phenotypic switching on glioblastoma growth and invasion. PLoS Comput Biol. 2012;8(6):e1002556. doi: 10.1371/journal.pcbi.1002556. Epub 2012 Jun 14. PMID: 22719241; PMCID: PMC3375261.
Jörnsten R, Abenius T, Kling T, Schmidt L, Johansson E, Nordling TE, Nordlander B, Sander C, Gennemark P, Funa K, Nilsson B, Lindahl L, Nelander S. Network modeling of the transcriptional effects of copy number aberrations in glioblastoma. Mol Syst Biol. 2011 Apr 26;7:486. doi: 10.1038/msb.2011.17. PMID: 21525872; PMCID: PMC3101951.
Nelander S, Wang W, Nilsson B, She QB, Pratilas C, Rosen N, Gennemark P, Sander C. Models from experiments: combinatorial drug perturbations of cancer cells. Mol Syst Biol. 2008;4:216. doi: 10.1038/msb.2008.53. Epub 2008 Sep 2. PMID: 18766176; PMCID: PMC2564730.